On December 15, 2025, Ipsen (ADR: IPSEY) announced that it has acquired exclusive global development, manufacturing and commercialization rights for SIM0613, a LRRC15-targeting antibody-drug conjugate licensed from Simcere Zaiming. Under the agreement, Ipsen will lead all clinical development activities outside Greater China, with first-in-human studies expected to commence in mid-2027. The deal adds a novel modality to Ipsen’s oncology pipeline, increasing its early-stage programme count to 12 candidates across five tumour targets. Ipsen has committed up to $60 million in upfront and milestone payments and will finance all subsequent R&D costs, in exchange for tiered low-double-digit royalties on net sales. This strategic acquisition reinforces Ipsen’s position in targeted cytotoxic therapies and underpins its goal to launch two new oncology assets by 2030.